

# UNITED STATES EPARTMENT OF COMMERCE

United States Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS

Washington, D.C. 20231

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR		AT	ATTORNEY DOCKET NO.	
09/673,87	2 12/04/00	WAI-CHIU SO		Ť	A33477 PCT (	
O21003 BAKER & BOTTS 30 ROCKEFELLER PLAZA NEW YORK NY 10112		HM12/1023 □		EX	AMINER	
			'	GOLLAM	UDI,S	
				ART UNIT	PAPER NUMBER	
				1616		
				DATE MAILED:	10/23/01	

Please find below and/or attached an Office communication concerning this application or proceeding.

**Commissioner of Patents and Trademarks** 

		<b>.</b>						
Office Action Summary		Application No.	Applicant(s)					
		09/673,872	WAI-CHIU SO ET AL.					
		Examiner	Art Unit					
		Sharmila S. Gollamudi	1616					
The MAILING DATE of this communication appears on the cover sheet with the correspondence address								
Period for Reply A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM								
THE   - Exte after - If the - If NO - Failu - Any	MAILING DATE OF THIS COMMUNICATION.  nsions of time may be available under the provisions of 37 CFR 1.13  SIX (6) MONTHS from the mailing date of this communication.  p period for reply specified above is less than thirty (30) days, a reply p period for reply is specified above, the maximum statutory period w re to reply within the set or extended period for reply will, by statute, reply received by the Office later than three months after the mailing and patent term adjustment. See 37 CFR 1.704(b).	36 (a). In no event, however, may a reply be tir within the statutory minimum of thirty (30) day rill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	nely filed s will be considered timely. the mailing date of this communication. D (35 U.S.C. § 133).					
1)⊠	Responsive to communication(s) filed on 04 E	<u> Pecember 2000</u> .						
2a) <u></u> □	This action is <b>FINAL</b> . 2b)⊠ This action is non-final.							
3)□	Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.							
Disposition of Claims								
4)⊠ Claim(s) <u>1-25</u> is/are pending in the application.								
4a) Of the above claim(s) is/are withdrawn from consideration.								
5)□	Claim(s) is/are allowed.							
6)⊠	)⊠ Claim(s) <u>1-25</u> is/are rejected.							
7)	Claim(s) is/are objected to.							
8)□	8) Claims are subject to restriction and/or election requirement.							
Application Papers								
9)🖂	9) The specification is objected to by the Examiner.							
10)	10) The drawing(s) filed on is/are objected to by the Examiner.							
11)	1) ☐ The proposed drawing correction filed on is: a) ☐ approved b) ☐ disapproved.							
12) The oath or declaration is objected to by the Examiner.								
Priority under 35 U.S.C. § 119								
13)⊠ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).								
a)⊠ All b)□ Some * c)□ None of:								
	1. Certified copies of the priority documents have been received.							
	2. $\boxtimes$ Certified copies of the priority documents have been received in Application No. $\underline{5}$ .							
Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).  * See the attempted detailed Office action for a list of the certified copies not received.								
* See the attached detailed Office action for a list of the certified copies not received.  14) Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).								
The Taking Medgerneric is made of a cidim for domestic priority dider 30 0.3.0. 8 113(e).								
Attachmen	t(c)							
15) Notice of References Cited (PTO-892)  18) Interview Summary (PTO-413) Paper No(s)								
16) 🔲 Not	ice of Draftsperson's Patent Drawing Review (PTO-948) rmation Disclosure Statement(s) (PTO-1449) Paper No(s) 6	19) Notice of Informal	Patent Application (PTO-152)					

Art Unit: 1616

#### **DETAILED ACTION**

Claims 1-25 are included in the prosecution of this application.

#### Specification

This application does not contain an abstract of the disclosure as required by 37 CFR 1.72(b). An abstract on a separate sheet is required.

### Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 1-20 and 25 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

A broad range or limitation together with a narrow range or limitation that falls within the broad range or limitation (in the same claim) is considered indefinite, since the resulting claim does not clearly set forth the metes and bounds of the patent protection desired. Note the explanation given by the Board of Patent Appeals and Interferences in *Ex parte Wu*, 10 USPQ2d 2031, 2033 (Bd. Pat. App. & Inter. 1989), as to where broad language is followed by "such as" and then narrow language. The Board stated that this can render a claim indefinite by raising a question or doubt as to whether the feature introduced by such language is (a) merely exemplary of the remainder of the claim, and therefore not required, or (b) a required feature of the claims. Note also, for example, the decisions of *Ex parte Steigewald*, 131 USPQ 74

Art Unit: 1616

(Bd. App. 1961); Ex parte Hall, 83 USPQ 38 (Bd. App. 1948); and Ex parte Hasche, 86 USPQ 481 (Bd. App. 1949). In the present instance, claim 1 recites the broad recitation and narrow limitation of "a pharmaceutically active component including as the pharmaceutically active component" and "a solvent composition including a solvent."

The recitation of 'minoxidil acetate or lactate salt' is unclear. Is minoxidil aceturate being claimed? Or the addition of acetic acid or lactic acid to form the salt?

Claim 25 is rejected under 35 U.S.C. 112, second paragraph, as being indefinite in that it fails to point out what is included or excluded by the claim language. This claim is an omnibus type claim.

# Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 1-9, 12-16, 18-19, and 21-23, 25 are rejected under 35 U.S.C. 102(b) as being anticipated by Yu et al (95571841).

Yu et al discloses a therapeutic composition for hair loss that includes minoxidil, water, ethanol, propylene glycol, and lactic acid. The pH of the composition taught is 4.7. The prior art reads on all instant amounts. (Note example 3 and col 6/7, line 44 through line 16). Yu et al discloses applying the composition to treat hair loss (col 18, line16-31)

Art Unit: 1616

# Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

Claims 10, 11, 17, 20, and 24 are rejected under 35 U.S.C. 103(a) as being unpatentable over Yu et al cited above, in view of Uchikawa et al (5156836).

As set forth above, Yu et al discloses a composition for the treatment of hair loss containing minoxidil and a solvent system.

Yu et al does not teach the use of benzyl alcohol as a solvent or the instant water/ethanol ratio.

Uchikawa et al teaches a hair tonic that contains an active agent such as minoxidil, organic acids such as lactic acid, water, polyhydric alcohols such as glycerin or propylene glycol, and alcohols such as ethanol and benzyl alcohol. Further, the reference teaches a formulation where the alcohol-water mixture is in the instant ratio. (col 3 and 4, line 45 through line 34). Uchikawa et al teaches the application of the hair composition for the treatment of hair loss.

It would have been obvious at the time the invention was made to use benzyl alcohol and ethanol in the solvent system since Uchikawa et al teaches the use of either alcohols in the hair tonic. One would be motivated to do so since both references teach the hair treatment compositions, in which the formulations are similar.

Art Unit: 1616

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Sharmila S. Gollamudi whose telephone number is (703) 305-2147. The examiner can be normally reached on M-F from 7:30am to 4:30pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jose Dees, can be reached at (703) 308-4628. The fax number for the organization where this application or proceeding is assigned is (703) 308-4556.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist, whose telephone number is (703) 308-1235.

SSG

SUPERVISORY PATENT EXAMINER